Faria MHG, Dria-Netto RH, Osugue GJ, de Souza Queiroz L, Chaddad-Neto FE
Ricca, V., Mannucci, E., Moretti, S., Di Bernardo, M., Zucchi, T., Cabras, P
18(2):185 Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review Seiwerth S, Rucman R, Turkovic B, et al., Current Pharmaceutical Design , 2018
Specifically, targeting key antioxidant proteins, such as SLC7A11, GCLC, GPX4, TXN, and TXNRD, represents an emerging approach for inducing oxidative cell death in cancer cells
Multiple clinical studies show EVOO increases postprandial GLP-1 and PYY (satiety hormones) while reducing ghrelin (the hunger hormone), through mechanisms that partially overlap with what GLP-1 drugs do pharmacologically